[A19-80] Elotuzumab (multiple myeloma) - Benefit assessment according to §35a Social Code Book V
Last updated 02.01.2020
Commission awarded on 20.09.2019 by the Federal Joint Committee (G-BA).
Adult patients with relapsed and refractory multiple myeloma after at least 2 prior therapies (including lenalidomide and a proteasome inhibitor) and disease progression on the last therapy
Only positive effects (in mortality and side effects), indication of minor added benefit
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
|Elotuzumab (multiple myeloma) - Addendum to Commission A19-80
|Elotuzumab - Benefit assessment according to §35a Social Code Book V
|Elotuzumab (multiple myeloma) - Benefit assessment according to §35a Social Code Book V (expiry of the decision)